U.S. antitrust regulators cleared the Pfizer (PFE), Wyeth (WYE) merger
More News related to PFE
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
- Standpoint Raised Its FY10 Price Target on Pfizer (PFE) to $24
- Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
More News related to WYE
- Progenics Announces Third Quarter 2009 Financial Results
- Pfizer (PFE) Completes Acquisition of Wyeth (WYE)
- Pfizer Completes Acquisition Of Wyeth
- U.S. antitrust regulators cleared the Pfizer (PFE), Wyeth (WYE) merger
- Progenics Pharma (PGNX) Regains RELISTOR Rights from Wyeth (WYE)
More News related to Mergers and Acquisitions
- Maxim Group Initiates Coverage on Golden Green Enterprises (CHOP) with a Buy
- Hilliard Lyons Initiates Coveage on Approach Resources (AREX) with a Buy
- Wells Fargo Transfers Coverage on Intuitive Surgical (ISRG) to a Market Perform; Raises Valuation Range
- Wedbush Initiates Coverage on Coinstar (CSTR) with an Outperform
- Thomas Weisel Starts FARO Tech. (FARO) at Overweight, $24 Price Target
U.S. antitrust regulators cleared the Pfizer (NYSE: PFE), Wyeth (NYSE: WYE) merger.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
